Yirui Sun

North China University of Science and Technology — China

Medicine · Health Sciences

3h-index390citations48works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(32), HIV Research and Treatment(4), HIV/AIDS drug development and treatment(2), Immunotherapy and Immune Responses(2), Cancer-related Molecular Pathways(2)

Publications48 total

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025Open Access
Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025Open Access
Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025Open Access
Figures S1-S8 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025Open Access
Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025Open Access
Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025Open Access
Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025Open Access
TE-like DNA methylation of highly expressed endosperm genes in maize
2025Open Access
[Progress in the heterologous synthesis of sesquiterpenes by <i>Yarrowia lipolytica</i>].
PubMed·2025
Table S6 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
Table S2 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
Data from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
Table S4 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
Table S1 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
Table S3 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
Table S6 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
Figures S1-S8 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
Table S5 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
Table S3 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
Table S5 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024Open Access
page 1 of 3Next →

Frequent Co-authors

Xiaoqing Cheng(39), Maureen Highkin(39), Nagalaxmi Vemalapally(39), Xiaohua Jin(39), Brandon Zhou(39), Julie L. Prior(39), Ashley R. Tipton(39), Shunqiang Li(39), Anton Iliuk(39), Samuel Achilefu(39), Ian S. Hagemann(39), John R. Edwards(39), Ron Bose(39), I Srivastava(2), Elaine Kan(2), Susan W. Barnett(2), Nancy Sullivan(1), Jingchun Li(1), Wolfgang Hofmann(1), Joseph Sodroski(1)